查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026755

2034年綜合代謝檢測市場預測－按檢測類型、疾病、最終用戶和地區分類的全球分析

Comprehensive Metabolic Panel Testing Market Forecasts to 2034 - Global Analysis By Test Type, Disease, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球綜合代謝指標檢測市場規模將達到 155 億美元，並在預測期內以 11.1% 的複合年成長率成長，到 2034 年將達到 360 億美元。

綜合代謝檢查（CMP）是一種血液診斷測試，可對個體的代謝健康狀況進行詳細評估。此測試評估與血糖值、電解質平衡和器官功能相關的多種指標。 CMP 通常包括測量血糖值、電解質以及肝臟、腎臟和血液中蛋白質水平的檢測。此外，該檢查還能提供有關肝臟和腎臟等重要器官整體健康狀況的重要信息，從而幫助識別和監測糖尿病、肝病和腎後續觀察等疾病。

根據國際糖尿病聯盟（IDF）的數據，全球有超過5.4億人患有糖尿病，預計到2045年，這一數字將超過7.8億人。

代謝性疾病增加

綜合代謝指標檢測（CMP）市場的主要促進因素之一是全球代謝性疾病（包括糖尿病、肥胖症和非酒精性脂肪肝）盛行率的不斷上升。此外，鑑於與這些疾病相關的生活方式和飲食習慣日益普遍，定期進行代謝指標檢測對於早期發現、介入和有效疾病管理至關重要。

缺乏教育和意識

儘管預防醫學日益受到重視，但人們對全面代謝檢測的重要性仍存在顯著的認知差距。醫護人員和公眾對這些檢測所提供的豐富數據及其在疾病早期發現中的重要性缺乏了解，阻礙了這些檢測的廣泛應用。此外，克服這項挑戰需要進行有針對性的宣傳宣傳活動，面向公眾和醫護人員，以提高他們對代謝健康監測的認知，並鼓勵他們積極參與。

標靶治療和個人化醫療

個人化醫療的日益普及為市場帶來了巨大的機會。隨著分子診斷和基因譜分析技術的不斷進步，將代謝譜數據與個別基因資訊結合，將顯著提高治療方案的精確度。此外，這將有助於開發針對每位患者特定代謝特徵的標靶治療，從而提高療效並減少副作用。

價格壓力與競爭環境

綜合代謝放射學檢測（CMP）市場正面臨來自產業競爭和價格壓力的巨大威脅。診斷公司之間激烈的價格競爭可能會危及綜合代謝檢測服務的長期生存能力。此外，為了在競爭激烈的市場中生存下來，同時又不影響客戶滿意度，實驗室必須實施成本削減策略、附加價值服務並實現策略差異化。

新冠疫情的影響：

新冠疫情從多個方面影響了市場。初期，醫療服務中斷、供應鏈問題以及為應對疫情而調整的醫療優先事項導致常規診斷檢測（包括臨床藥物檢測）暫時下降。隨著醫療行業適應“新常態”，人們越來越認知到全面代謝評估在確定新冠疫情影響方面的重要性，尤其是在存在代謝併發症的患者中。此外，疫情也推動了就地檢驗、遠端醫療和數位健康解決方案的快速發展，從而改變了臨床藥物檢測市場的趨勢。

在預測期內，糖尿病細分市場預計將是規模最大的。

糖尿病是一種高發慢性疾病，因此預計將佔據最大的市場佔有率。糖尿病是一種代謝性疾病，影響全球數百萬人口，其特徵是血糖值升高。此外，糖尿病管理市場提供種類繁多的產品和服務，包括處方藥、血糖值儀、胰島素治療和生活方式干涉。由於久坐不動的生活方式和不健康的飲食習慣等因素導致糖尿病盛行率不斷上升，因此，人們正在加大對疾病管理研發和創新方法的投入。

在預測期內，即時護理中心 (POC) 細分市場預計將呈現最高的複合年成長率。

即時檢測中心（POC）細分市場呈現最高的複合年成長率。即時檢測因其易用性、速度快、能夠簡化醫療服務流程而日益普及。這種檢測的特點是診斷迅速，且可在患者所在位置或附近即時獲得結果。這些中心提供廣泛的診斷服務，幾分鐘內即可獲得結果。這些服務包括血液檢測、尿液檢查和其他必要的檢測。此外，醫療服務去中心化、改善病患就醫途徑以及縮短診斷時間的日益重視，也推動了即時檢測中心的擴張。

市佔率最大的地區：

預計北美將佔據慢性代謝疾病 (CMP) 檢測市場的最大佔有率。該地區佔據主導地位的因素包括：龐大的慢性代謝疾病患者群體、完善的醫療保健基礎設施以及較高的預防醫學意識。此外，技術進步、主要行業參與者的存在以及有利的報銷機制也促進了北美 CMP 檢測市場的擴張。

複合年成長率最高的地區：

預計亞太地區的綜合代謝指標檢測（CMP）市場將以最高的複合年成長率成長。推動這一成長的因素包括人口快速成長、健康意識不斷提高以及代謝性疾病患病率上升。亞太地區對綜合代謝指標檢測需求的激增部分歸功於醫療基礎設施的改善和尖端診斷技術的廣泛應用。此外，文明病盛行率的上升以及對早期檢測和管理的日益重視，預計也將推動該地區市場的強勁成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球綜合代謝檢測市場：依檢測類型分類

  • 葡萄糖
  • 鈣
  • 電解質
    • 鈉
    • 鉀
    • 其他電解質
  • 腎功能檢查
    • 血中尿素氮（BUN）
    • 肌酸酐
  • 肝功能檢查
    • 白蛋白
    • 膽紅素
    • 鹼性磷酸酶
    • 天門冬胺酸胺基轉移酶（AST）
    • 丙胺基轉移酶（ALT）
  • 蛋白質
  • 其他類型的測試

第6章 全球綜合代謝檢測市場：依疾病分類

  • 糖尿病
  • 腎臟疾病
  • 肝病
  • 其他疾病

第7章 全球綜合代謝指標檢測市場：依最終用戶分類

  • 照護端中心
  • 診斷檢查室
  • 醫院
  • 其他最終用戶

第8章 全球綜合代謝指標檢測市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第9章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：公司簡介

  • Charles River Laboratories Inc.
  • Genoptix Inc.
  • Baptist Health Medical Group
  • ARUP Laboratories
  • Scion Lab Services LLC
  • NeoGenomics Laboratories, Inc.
  • Abbott Laboratories
  • Unipath
  • Siemens HealthCare GmbH
  • Nova Medical
  • CENTOGENE NV
  • Quest Diagnostics Incorporated
  • Cleveland HeartLab, Inc.
  • Sonic HealthCare
  • TCG Corp.
  • SYNLAB International GmbH
Product Code: SMRC24748

According to Stratistics MRC, the Global Comprehensive Metabolic Panel Testing Market is accounted for $15.5 billion in 2026 and is expected to reach $36.0 billion by 2034 growing at a CAGR of 11.1% during the forecast period. A diagnostic blood test called a Comprehensive Metabolic Panel (CMP) offers a thorough assessment of a person's metabolic health. It assesses a number of markers linked to blood sugar, electrolyte balance, and organ function. Tests for glucose, electrolytes, and liver, kidney, and protein levels in the blood are commonly included in a CMP. Moreover, this panel helps identify and track diseases like diabetes, liver disease, and kidney dysfunction by providing insightful information about the general health of important organs like the liver and kidneys.

According to International Diabetes Federation (IDF), over 540 million people are suffering from diabetes worldwide, and by 2045 the numbers are expected to cross 780 million marks.

Market Dynamics:

Driver:

Increased frequency of metabolic illnesses

One major factor propelling the market for Comprehensive Metabolic Panel (CMP) testing is the rising prevalence of metabolic disorders worldwide, such as diabetes, obesity, and non-alcoholic fatty liver disease. Additionally, regular metabolic profiling is imperative to facilitate early detection, intervention, and efficient disease management, given the increasing prevalence of lifestyle factors and dietary patterns associated with these conditions.

Restraint:

Low level of education and awareness

Even with the growing focus on preventive healthcare, there is still a significant knowledge gap about the significance of full metabolic panel testing. The lack of awareness among healthcare professionals and the general public regarding the comprehensive range of data these tests offer and their significance in the early identification of illnesses impedes their use. Furthermore, in order to overcome this limitation, focused education campaigns that foster knowledge and proactive participation in metabolic health monitoring are required, aimed at both the general public and healthcare professionals.

Opportunity:

Targeted therapies and personalized medicine

There is a big chance for the market because of the growing emphasis on personalized medicine. The precision of treatment plans can be improved by combining metabolic panel data with individual genetic information as molecular diagnostics and genetic profiling continue to advance. Moreover, this makes it possible to develop targeted therapies that are suited to each patient's particular metabolic profile, enhancing treatment effectiveness and reducing side effects.

Threat:

Pricing pressure and the competitive environment

The CMP testing market is significantly threatened by the industry as well as pricing pressures. A pricing war amongst diagnostic companies could jeopardize the long-term viability of comprehensive metabolic panel testing services due to intense competition. Additionally, laboratories must use cost-cutting strategies, value-added services, and strategic differentiation to survive in this cutthroat market without sacrificing customer satisfaction.

Covid-19 Impact:

There are several ways in which the COVID-19 pandemic has affected the market. A brief drop in routine diagnostic testing, including CMP tests, was initially caused by disruptions in healthcare services, issues with the supply chain, and a change in healthcare priorities toward managing the pandemic. The significance of thorough metabolic assessments in determining the effects of COVID-19 on patients, particularly those with metabolic complications, was acknowledged more as the healthcare sector adjusted to the new normal. Furthermore, point-of-care testing, telemedicine, and digital health solutions have all seen rapid adoption as a result of the pandemic, which has changed the dynamics of the CMP testing market.

The Diabetes segment is expected to be the largest during the forecast period

Due to the fact that diabetes is a chronic condition with a high prevalence, it is expected to hold the largest share of the market. Diabetes is a metabolic disease that affects millions of people worldwide and is typified by elevated blood glucose levels. Moreover, a broad range of goods and services are available in the diabetes management market, such as prescription drugs, glucose monitors, insulin treatments, and lifestyle modifications. Significant investments have been made in research, development, and creative approaches to disease management as a result of the rising prevalence of diabetes, which is fueled by factors like sedentary lifestyles and poor dietary habits.

The Point of care Centers segment is expected to have the highest CAGR during the forecast period

The market's highest CAGR is being seen in the point-of-care centers segment. Point-of-care testing has become increasingly popular because of its ease of use, speed, and capacity to simplify the delivery of healthcare. It is typified by quick diagnostics and real-time results at or close to the patient. These facilities provide a broad range of diagnostic services, with results available in a matter of minutes. These services include blood tests, urinalysis, and other crucial assessments. Additionally, point-of-care center expansion has been driven by the growing emphasis on decentralizing healthcare services, increasing patient accessibility, and shortening diagnosis turnaround times.

Region with largest share:

The market for CMP testing is expected to have the largest share in the North American region. A large patient population with chronic metabolic conditions, a well-established healthcare infrastructure, and a high level of awareness regarding preventive healthcare are some of the factors contributing to the region's dominance. Furthermore, technology developments, the existence of major industry players, and advantageous reimbursement practices have all aided in the expansion of the CMP testing market in North America.

Region with highest CAGR:

The comprehensive metabolic panel (CMP) testing market is expected to grow at the highest CAGR in the Asia-Pacific region. A number of factors are driving the region's growth, such as a quickly growing population, growing healthcare awareness, and an increase in the prevalence of metabolic disorders. The Asia-Pacific region's burgeoning need for comprehensive metabolic panel testing is partly due to improved healthcare infrastructure and the uptake of cutting-edge diagnostic technologies. Moreover, the market in this region is expected to grow at a robust rate due to the increasing prevalence of lifestyle-related diseases and the growing emphasis on early detection and management.

Key players in the market

Some of the key players in Comprehensive Metabolic Panel Testing market include Charles River Laboratories Inc., Genoptix Inc., Baptist Health Medical Group, ARUP Laboratories, Scion Lab Services LLC, NeoGenomics Laboratories, Inc., Abbott Laboratories, Unipath, Siemens Healthcare GmbH, Nova Medical, CENTOGENE N.V., Quest Diagnostics Incorporated, Cleveland HeartLab, Inc., Sonic Healthcare, TCG Corp. and SYNLAB International GmbH.

Key Developments:

In December 2023, Charles River Laboratories International, Inc. announced an important milestone in their strategic collaboration to manufacture CASGEVY(TM). CASGEVY is approved in some countries for certain eligible patients. The news follows Charles River's Memphis center of excellence passing back-to-back audits from both the U.S. Food and Drug Administration and the Health Products Regulatory Authority, on behalf of the European Medicines Agency.

In December 2023, Baptist Health Baptist Hospital launched the Inspiration Hall, powered by national leader in hospice and palliative care services, VITAS Healthcare. Located on the first floor near the hospital's imaging center waiting room, the Inspiration Hall is an immersive experience where patients, visitors and hospital team members can submit, read or watch messages of comfort and support that will inspire others in their health journey.

In December 2023, A partnership between ARUP Laboratories and Medicover has made a new companion diagnostic, and thereby a new gene therapy, more accessible to patients in the European Union. ARUP Laboratories, in close collaboration with BioMarin Pharmaceutical Inc., developed AAV5 DetectCDx(TM), a companion diagnostic that aids in the selection of adult patients with severe hemophilia A who are eligible for treatment with ROCTAVIAN(TM), a new gene therapy developed by BioMarin.

Test Types Covered:

  • Glucose
  • Calcium
  • Electrolytes
  • Kidney Function Tests
  • Liver Function Tests
  • Proteins
  • Other Test Types

Diseases Covered:

  • Diabetes
  • Kidney Disease
  • Liver Disease
  • Other Diseases

End Users Covered:

  • Point of Care Centers
  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Comprehensive Metabolic Panel Testing Market, By Test Type

  • 5.1 Introduction
  • 5.2 Glucose
  • 5.3 Calcium
  • 5.4 Electrolytes
    • 5.4.1 Sodium
    • 5.4.2 Potassium
    • 5.4.3 Other Electrolytes
  • 5.5 Kidney Function Tests
    • 5.5.1 Blood Urea Nitrogen (BUN)
    • 5.5.2 Creatinine
  • 5.6 Liver Function Tests
    • 5.6.1 Albumin
    • 5.6.2 Bilirubin
    • 5.6.3 Alkaline Phosphatase
    • 5.6.4 Aspartate Aminotransferase (AST)
    • 5.6.5 Alanine Aminotransferase (ALT)
  • 5.7 Proteins
  • 5.8 Other Test Types

6 Global Comprehensive Metabolic Panel Testing Market, By Disease

  • 6.1 Introduction
  • 6.2 Diabetes
  • 6.3 Kidney Disease
  • 6.4 Liver Disease
  • 6.5 Other Diseases

7 Global Comprehensive Metabolic Panel Testing Market, By End User

  • 7.1 Introduction
  • 7.2 Point of Care Centers
  • 7.3 Diagnostic Laboratories
  • 7.4 Hospitals
  • 7.5 Other End Users

8 Global Comprehensive Metabolic Panel Testing Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Charles River Laboratories Inc.
  • 10.2 Genoptix Inc.
  • 10.3 Baptist Health Medical Group
  • 10.4 ARUP Laboratories
  • 10.5 Scion Lab Services LLC
  • 10.6 NeoGenomics Laboratories, Inc.
  • 10.7 Abbott Laboratories
  • 10.8 Unipath
  • 10.9 Siemens HealthCare GmbH
  • 10.10 Nova Medical
  • 10.11 CENTOGENE N.V.
  • 10.12 Quest Diagnostics Incorporated
  • 10.13 Cleveland HeartLab, Inc.
  • 10.14 Sonic HealthCare
  • 10.15 TCG Corp.
  • 10.16 SYNLAB International GmbH

List of Tables

  • Table 1 Global Comprehensive Metabolic Panel Testing Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Comprehensive Metabolic Panel Testing Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 3 Global Comprehensive Metabolic Panel Testing Market Outlook, By Glucose (2023-2034) ($MN)
  • Table 4 Global Comprehensive Metabolic Panel Testing Market Outlook, By Calcium (2023-2034) ($MN)
  • Table 5 Global Comprehensive Metabolic Panel Testing Market Outlook, By Electrolytes (2023-2034) ($MN)
  • Table 6 Global Comprehensive Metabolic Panel Testing Market Outlook, By Sodium (2023-2034) ($MN)
  • Table 7 Global Comprehensive Metabolic Panel Testing Market Outlook, By Potassium (2023-2034) ($MN)
  • Table 8 Global Comprehensive Metabolic Panel Testing Market Outlook, By Other Electrolytes (2023-2034) ($MN)
  • Table 9 Global Comprehensive Metabolic Panel Testing Market Outlook, By Kidney Function Tests (2023-2034) ($MN)
  • Table 10 Global Comprehensive Metabolic Panel Testing Market Outlook, By Blood Urea Nitrogen (BUN) (2023-2034) ($MN)
  • Table 11 Global Comprehensive Metabolic Panel Testing Market Outlook, By Creatinine (2023-2034) ($MN)
  • Table 12 Global Comprehensive Metabolic Panel Testing Market Outlook, By Liver Function Tests (2023-2034) ($MN)
  • Table 13 Global Comprehensive Metabolic Panel Testing Market Outlook, By Albumin (2023-2034) ($MN)
  • Table 14 Global Comprehensive Metabolic Panel Testing Market Outlook, By Bilirubin (2023-2034) ($MN)
  • Table 15 Global Comprehensive Metabolic Panel Testing Market Outlook, By Alkaline Phosphatase (2023-2034) ($MN)
  • Table 16 Global Comprehensive Metabolic Panel Testing Market Outlook, By Aspartate Aminotransferase (AST) (2023-2034) ($MN)
  • Table 17 Global Comprehensive Metabolic Panel Testing Market Outlook, By Alanine Aminotransferase (ALT) (2023-2034) ($MN)
  • Table 18 Global Comprehensive Metabolic Panel Testing Market Outlook, By Proteins (2023-2034) ($MN)
  • Table 19 Global Comprehensive Metabolic Panel Testing Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 20 Global Comprehensive Metabolic Panel Testing Market Outlook, By Disease (2023-2034) ($MN)
  • Table 21 Global Comprehensive Metabolic Panel Testing Market Outlook, By Diabetes (2023-2034) ($MN)
  • Table 22 Global Comprehensive Metabolic Panel Testing Market Outlook, By Kidney Disease (2023-2034) ($MN)
  • Table 23 Global Comprehensive Metabolic Panel Testing Market Outlook, By Liver Disease (2023-2034) ($MN)
  • Table 24 Global Comprehensive Metabolic Panel Testing Market Outlook, By Other Diseases (2023-2034) ($MN)
  • Table 25 Global Comprehensive Metabolic Panel Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 26 Global Comprehensive Metabolic Panel Testing Market Outlook, By Point of Care Centers (2023-2034) ($MN)
  • Table 27 Global Comprehensive Metabolic Panel Testing Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 28 Global Comprehensive Metabolic Panel Testing Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 29 Global Comprehensive Metabolic Panel Testing Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.